Bank of New York Mellon
ACTU

Bank of New York Mellon’s Actuate Therapeutics ACTU Stock Holding History

Bank of New York Mellon’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15,416
Closed -$42.2K – 4454
2026
Q1 		$42.2K Buy
15,416
+2,851
+23% +$11.8K ﹤0.01% 4150
2025
Q4 		$76.9K Buy
+12,565
New +$86.3K ﹤0.01% 4122

Other funds holding ACTU

TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCG
Rock Creek Group Washington, District of Columbia $994M AUM 11.29% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GG
Gleason Group Prospect, Kentucky $1.15B AUM 21.11% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
AA
ACT Advisors Asheville, North Carolina $301M AUM 23.36% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Bank of New York Mellon's ACTU Position: Q2 2026 in Review

Bank of New York Mellon sold out of Actuate Therapeutics (ACTU) in Q2 2026, closing a stake of 15,416 shares — an estimated $42.2K sold.

Bank of New York Mellon first reported a position in ACTU in Q4 2025 and held it in 2 quarters. The position peaked at $76.9K in Q4 2025. 31 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • Bank of New York Mellon reported no remaining Actuate Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Bank of New York Mellon sold 15,416 Actuate Therapeutics shares in Q2 2026, an estimated $42.2K.
  • Bank of New York Mellon first reported a position in Actuate Therapeutics in Q4 2025 and held it in 2 quarters.
  • Bank of New York Mellon's Actuate Therapeutics position peaked at $76.9K in Q4 2025.
  • 31 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.